There’s a distinct line between the ability to conduct big data analytics and the ability to engage in the next step of true clinical decision support. “Big data” is an inherently misleading term, since “big” refers not to the volume of data but to the number of sources that can be combined to produce completely new insights. Big data analytics can be (1) descriptive, (2) predictive, or (3) prescriptive analytics reflective of what has already happened, what is likely happen, and what they can do about it, respectively. The ability to close the gap between research data and clinical actionable data is essential but it's a burden. This is your opportunity to listen to the experts and participate in an open and stimulating discussion.
5:30 p.m. - 6:30 p.m. Networking
6:30 p.m.- 7:30 p.m. Panel discussion
7:30 p.m.- 8:00 p.m. Open discussion
Anna Barker, Ph.D. is co-director of Complex Adaptive Systems – Biomedicine, Director of the National Biomarker Development Alliance and Professor at Arizona State University where she designs and implements new research knowledge networks, projects and models to address major problems in biomedical research and biomedicine. She currently focuses on complex systems science as applied to the discovery and systems development of biomarkers, next-generation clinical trials and the applications of artificial intelligence and advanced analytics to improve biomarker discovery. Prior to ASU, she served as the Deputy Director for Strategic Scientific Initiatives for the National Cancer Institute (NCI)/National Institutes of Health (NIH), The Cancer Genome Atlas (TCGA) and was responsible for the NCI’s international cancer research programs. Dr. Barker has served on a number of boards including but not limited to: Member, Board of Trustees, Sanford Burnham Prebys Institute; Friends of Cancer Research Board of Directors; Senior Fellow, Milken Institute, Faster Cures; Board Member, Quantum Leap Health Collaborative (ISPY 2 trials network); Chair, Data Standards Committee and Advisor, Biden Cancer Initiative; and Program Advisor; Member, and member of the Caris Scientific Advisory Board. Dr. Barker received her M.A. and Ph.D. at the Ohio State University, where she trained in immunology and microbiology.
Wendy Benson is Vice President, Strategic Initiatives at Rady Children’s Institute of Genomic Medicine. She is a clinical and life science industry executive with more than 25 years’ experience including time at large multinational companies such as Johnson & Johnson, Roche Diagnostics, Illumina and Thermo Fisher Scientific along with start-up and mid-sized companies with niche molecular diagnostic products. She has worked with mature as well as emerging technologies in geographies around the world. In her role at the Institute, she is the business lead in working with many external partners include multiple Children’s Hospitals in the United States as well as some ex-US national health systems. With her networked industry experience, she also is focused on getting early access for new products (chemistries, software or other tools) for evaluation and enhancements in the pediatric rare disease clinical application.
Steve Grossman is co-founder of ADCY5.org and advocates for patient-driven rare disease efforts. ADCY5-induced Dyskinesia, caused by a variant in the ADCY5 gene, is often misdiagnosed as cerebral palsy, mitochondrial disease, and other movement disorders. His daughter, Lilly, is affected by the condition and was an early undiagnosed patient that was diagnosed via whole genome sequencing. She is featured in articles in National Geographic, The Atlantic, The LA Times, and The Union Tribune. He applies his experience in pharmacy software, laboratory equipment, and aerospace software to rare disease data management as it relates to clinical care, patient registries for under-served conditions, natural history studies, participation in N-of-1 precision medicine projects, iPSC projects, and continuing to find affected individuals. The ADCY5.org group looks to manage data in a way that fosters collaboration across the spectrum of patients, clinicians, and researchers to find a treatment or a cure.
Dawn Barry is the co-founder of LunaDNA, a community-owned platform to securely store and share personal health data for health and quality of life research. Prior to LunaDNA, Dawn served as the vice president of Applied Genomics at Illumina, Inc.
Kelly Theel, Ph.D. is a Senior Regulatory Affairs Officer at IQVIA’s Orphan Drug Unit. She specializes in submissions to the FDA (Orphan Drug, Pediatric Rare Disease, Fast Track, Breakthrough, and Regenerative Medicine Advanced Therapy designations) and EMA (Orphan Drug designation and Priority Medicines). She also designs strategies around client data, both pre-clinical and clinical, to help drug discovery firms take advantage of agency incentives promoting research that will deliver effective therapies to patients with rare diseases or unmet medical need. As of November 2018, she has played a critical role in over 150 submissions to government agencies.
- Members: $15
- Non-members: $45
Special Pricing for Guests
Members can register guests at member price.
Online Registration Deadline
February 26, 2019